Skip to content
Triangle logo TriangleGet started
← Full study record

NCT04401579 · OUTCOME

Duration of Oxygen Use

Adaptive COVID-19 Treatment Trial 2 (ACTT-2) · Source last updated 2022-03-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Days
Interval / dispersion
Inter-Quartile Range
Time frame
Day 1 through Day 29

What was measured

Duration of oxygen use was measured in days among participants who were on oxygen in based, calculated in two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die.

Analysis population: The analysis population is restricted to randomized participants who were on oxygen at baseline.

Groups in this outcome

Remdesivir Plus Baricitinib

200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.

Remdesivir Plus Placebo

200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Remdesivir Plus Baricitinib445
Remdesivir Plus Placebo446

Reported measurements

Including imputations for participants who died

Analysis denominator · Participants

GroupSource count
Remdesivir Plus Baricitinib445
Remdesivir Plus Placebo446
Values in Days · Interval/dispersion: Inter-Quartile Range
GroupValueSpreadLowerUpperComment
Remdesivir Plus Baricitinib10Not reported427Not reported
Remdesivir Plus Placebo12Not reported428Not reported
Among participants who did not die

Analysis denominator · Participants

GroupSource count
Remdesivir Plus Baricitinib421
Remdesivir Plus Placebo409
Values in Days · Interval/dispersion: Inter-Quartile Range
GroupValueSpreadLowerUpperComment
Remdesivir Plus Baricitinib9Not reported424Not reported
Remdesivir Plus Placebo10Not reported428Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        4
        upper Limit
        27
        value
        10
      2. group Id
        OG001
        lower Limit
        4
        upper Limit
        28
        value
        12
    denoms
    1. counts
      1. group Id
        OG000
        value
        445
      2. group Id
        OG001
        value
        446
      units
      Participants
    title
    Including imputations for participants who died
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        4
        upper Limit
        24
        value
        9
      2. group Id
        OG001
        lower Limit
        4
        upper Limit
        28
        value
        10
    denoms
    1. counts
      1. group Id
        OG000
        value
        421
      2. group Id
        OG001
        value
        409
      units
      Participants
    title
    Among participants who did not die
denoms
  1. counts
    1. group Id
      OG000
      value
      445
    2. group Id
      OG001
      value
      446
    units
    Participants
description
Duration of oxygen use was measured in days among participants who were on oxygen in based, calculated in two ways. The first includes imputations for participants who died. The second method is restricted to participants who did not die.
dispersion Type
Inter-Quartile Range
groups
  1. description
    200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.
    id
    OG000
    title
    Remdesivir Plus Baricitinib
  2. description
    200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.
    id
    OG001
    title
    Remdesivir Plus Placebo
param Type
MEDIAN
population Description
The analysis population is restricted to randomized participants who were on oxygen at baseline.
reporting Status
POSTED
time Frame
Day 1 through Day 29
title
Duration of Oxygen Use
type
SECONDARY
unit Of Measure
Days

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice